Establishing Causation in Transfusion Medicine and Related Tribulations

Transfusion Medicine Reviews

Volumn 25, Issue 2, 2011, Pages 81-88

  Vamvakas, Eleftherios C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ERYTHROPOIETIN;

ADVERSE OUTCOME; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CIGARETTE SMOKING; EDITORIAL; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEART INFARCTION; HIP FRACTURE; HUMAN; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LUNG EDEMA; MEDICAL PRACTICE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; SEPSIS; TRANSFUSION RELATED ACUTE LUNG INJURY;

BLOOD BANKS; BLOOD TRANSFUSION; CAUSALITY; CRITICAL CARE; ERYTHROCYTES; EVIDENCE-BASED MEDICINE; HUMANS; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK MANAGEMENT;

EID: 79952693813     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2010.11.010     Document Type: Editorial

References (52)

1. Surgenor S.D., Hampers M.J., Corwin H.L. Is blood transfusion good for the heart?. Crit Care Med 2001, 29:442-444.
2. Hébert P.C., Wells G., Blajchman M.A., et al. A multicenter randomized controlled trial of transfusion requirements in critical care. N Engl J Med 1999, 340:409-417.
3. Hébert P.C., Yetisir E., Martin C., et al. Is a low transfusion threshold safe in critically-ill patients in cardiovascular diseases?. Crit Care Med 2001, 29:227-234.
4. Carson J.L., Terrin M.L., Maganizer J., et al. Transfusion trigger trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS). Transfusion 2006, 46:2192-2206.
5. FDA/CBER Fatalities reported to the FDA following blood collection and transfusion: annual summary for fiscal year 2009 Accessed 2 Nov 2010. http://www.fda.gov/download/BiologicsBloodVaccines/SafetyAvailability/Reportaproblem/TransfusionDonationFatalities/UCM205620.pdf.
6. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: the on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113:3406-3417.
7. Vamvakas E.C., Blajchman M.A. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transf Med Rev 2010, 24:77-124.
8. Isbister J.P., Shander A., Spahn D.R., et al. Adverse blood transfusion outcomes: Establishing causation. Transf Med Rev 2011, 25:89-101.
9. Jackson G.N., Snowden C.A., Indrikovs A.J. Prospective audit program to determine blood component transfusion appropriateness at a large university hospital: A 5-year experience. Transf Med Rev 2008, 22:154-161.
10. Gombotz H., Rehak P., Shander A., et al. Blood use in elective surgery: The Austrian benchmark study. Transfusion 2007, 47:1468-1480.
11. Pape A., Habler O. Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol 2007, 21:221-239.
12. Vamvakas E.C., Blajchman M.A. Transfusion-related immunomodulation: An update. Blood Rev 2007, 21:327-348.
13. Doll R., Hill A.B. The mortality of doctors in relation to their smoking habits; A preliminary report. Br Med J 1954, 1:1451-1455.
14. Vamvakas E.C. Statistical associations and cause-and effect relationships. In: Vamvakas EC: Evidence-based practice of transfusion medicine 2001, 21-64. AABB Press, Bethesda (MD).
15. Benson K., Hartz A.J. A comparison of observational studies and randomized controlled trials. N Engl J Med 2000, 342:1878-1886.
16. Concato J., Shah N., Horwitz R.I. Randomized controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342:1887-1892.
17. Pocock S.J., Elbourne D.R. Randomized trials or observational tribulations?. N Engl J Med 2000, 342:1907-1909.
18. Colditz G.A., Miller J.N., Mosteller F. How study design affects outcomes in comparisons of therapy: I. Medical. Stat Med 1989, 8:441-454.
19. Miller J.N., Colditz G.A., Mosteller F. How study design affects outcomes in comparisons of therapy. II. Surgical. Stat Med 1989, 8:455-466.
20. Chalmers T.C., Matta R.J., Smith H., et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977, 297:1091-1096.
21. Bennet-Guerrero E., Stafford-Smith M., Waweru P., et al. A prospective, double-blind randomized feasibility clinical trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion 2009, 49:1375-1383.
22. Vamvakas E.C. Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") red blood cells: are we at equipoise?. Transfusion 2010, 50:600-610.
23. Zimrin A.B., Hess J. Current issues relating to the transfusion of stored red blood cells. Vox Sang 2009, 96:93-103.
24. Lelubre C., Piagnerelli M., Vincent J.L. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality?. Transfusion 2009, 49:1384-1394.
25. Schulman C.I., Nathe K., Brown M., et al. Impact of age of transfused blood in the trauma patient. J Trauma 2002, 52:1224-1225.
26. Walsh T.S., McArdle F., McLellan S.A., et al. Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemia of critically-ill patients?. Crit Care Med 2004, 32:364-371.
27. Mou S.S., Giroir B.P., Molitor-Kirsch E.A., et al. Fresh blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 2004, 351:1635-1644.
28. Hébert P.C., Chin-Yee I., Fergusson D., et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg 2005, 100:1433-1438.
29. Weiskopf R.B., Feiner J., Hopf H., et al. Fresh blood and aged storage blood are equally efficacious in immediately reversing anemia-induced brain oxygenation deficits in humans. Anesthesiology 2006, 104:911-920.
30. Basran S., Frumento R.J., Cohen A., et al. The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery. Anesth Analg 2006, 103:15-20.
31. Koch C.G., Li L., Sessler D.I., et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008, 358:1229-1239.
32. Spinella P., Carroll C., Staff I., et al. Increased deep-vein thrombosis and in-hospital mortality with the transfusion of old RBCs for patients with traumatic injuries. Crit Care 2009, 13:R151.
33. United Nations Conference on Environment and Development. Earth Summit. Rio Declaration on Environment and Development, Rio de Janeiro, Brazil, Publ. no. E.73II.A.14. Stockholm: United Nations, 1992.
34. Wilson K., Wilson M., Hébert P.C., et al. The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy. Transf Med Rev 2003, 17:89-94.
35. Stowell C.P., Jones S.C., Enny C., et al. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: Safety analysis. Spine 2009, 34:2479-2485.
36. Hershman D.L., Buono D.L., Malin J., et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009, 101:1633-1641.
37. Lipp G., Franchini M., Favaloro E.J. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010, 36:537-549.
38. van der Meer P., Groenveld H.F., Januzzi J.L., et al. Erythropoietin treatment in patients with chronic heart failure: A meta-analysis. Heart 2009, 95:1309-1314.
39. Boulton F.E., James V. Guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion. Transfus Med 2007, 17:354-365.
40. Carless P.A., Henry D.A., Moxey A.J., et al. Cell-salvage for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2006, 4:1-109.
41. Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion 2010, (Epub ahead of print, Aug 27).
42. Devine D., Jenkins G., Howe D., et al. Relative safety of buffy-coat platelet pools (letter). Transfusion 2010, 50:1591-1592.
43. Schrezenmeier H., Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: Which product type should be preferred?. Vox Sang 2010, 99:1-15.
44. Ness P.M., Campbell-Lee S.A. Single-donor versus pooled random-donor platelet concentrates. Curr Opin Hematol 2001, 8:392-396.
45. Vamvakas E.C. Relative safety of pooled whole-blood-derived versus single-donor (apheresis) platelets in the United States: A systematic review of disparate risks. Transfusion 2009, 49:2743-2758.
46. Popovsky M.A. Transfusion-related acute lung injury: Incidence, pathogenesis, and the role of multicomponent apheresis in its prevention. Transfus Med Hemother 2008, 35:76-79.
47. Vamvakas E.C. The ethics of wasting the donor's gift of buffy coat. Vox Sang 2010, (Epub ahead of print, Sep 3).
48. Zingsem J. Multi-component apheresis. ISBT Sci Ser 2010, 5:83-87.
49. AuBuchon J.P., Petz L.D. Making decisions to improve transfusion safety. Policy alternatives in transfusion medicine 2001, 193-226. AABB Press, Bethesda (MD). J.P. AuBuchon, L. Petz, A. Fink (Eds.).
50. Vamvakas E.C. Evidence-based practice of transfusion medicine: Is it possible and what do the words mean?. Transf Med Rev 2004, 18:267-278.
51. Passamani E. Clinical trials: Are they ethical?. N Engl J Med 1991, 324:1589-1591.
52. Culpepper L., Gilbert T.T. Evidence and ethics. Lancet 1999, 353:829-831.